Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
暂无分享,去创建一个
Stefanie Schreiber | Frank Schreiber | Allison Fero | William J Jagust | Susan M Landau | W. Jagust | S. Landau | F. Schreiber | S. Schreiber | Allison Fero
[1] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[2] Brenda L. Lyon,et al. A Conceptual Overview , 2011 .
[3] Philip S. Insel,et al. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. , 2015, Brain : a journal of neurology.
[4] A. Drzezga,et al. The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment. , 2013, Current Alzheimer research.
[5] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[6] Cindee M. Madison,et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.
[7] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[8] Rik Ossenkoppele,et al. Comparison of Simplified Parametric Methods for Visual Interpretation of 11C-Pittsburgh Compound-B PET Images , 2014, The Journal of Nuclear Medicine.
[9] J O Rinne,et al. Amyloid PET imaging in patients with mild cognitive impairment , 2011, Neurology.
[10] C. Rowe,et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.
[11] A. Wall,et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers , 2012, Neurology.
[12] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[13] A. Fagan,et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.
[14] Ronald Carl Petersen,et al. Mild cognitive impairment : aging to Alzheimer's disease , 2003 .
[15] Paul Edison,et al. A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[16] Lisa A. Weissfeld,et al. Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches , 2013, NeuroImage.
[17] M. Weiner,et al. Relationships between biomarkers in aging and dementia , 2009, Neurology.
[18] Gina N. LaRossa,et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.
[19] Jeffrey A. James,et al. Amyloid imaging in mild cognitive impairment subtypes , 2009, Annals of neurology.
[20] W. M. van der Flier,et al. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. , 2014, Journal of Alzheimer's disease : JAD.
[21] John Seibyl,et al. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[22] A. Rey. L'examen clinique in psychologie , 1964 .
[24] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[25] M. Mintun,et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid , 2013, Annals of neurology.
[26] Nick C Fox,et al. The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .
[27] R. Coleman,et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.
[28] H. Engler,et al. PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.
[29] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[30] R. Katz,et al. Regulatory innovation and drug development for early-stage Alzheimer's disease. , 2013, The New England journal of medicine.
[31] M. Mintun,et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline , 2012, Annals of neurology.
[32] Cindee M. Madison,et al. Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.
[33] Lennart Thurfjell,et al. Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.
[34] C. Rowe,et al. Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing , 2013, Annals of neurology.
[35] Richard J. Caselli,et al. Ushering in the study and treatment of preclinical Alzheimer disease , 2013, Nature Reviews Neurology.
[36] George Jewell,et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study , 2014, Molecular Psychiatry.
[37] Nick C Fox,et al. Conversion of amyloid positive and negative MCI to AD over 3 years , 2009, Neurology.
[38] Keith A. Johnson,et al. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline , 2012, Neurology.